Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Sponsor
Fudan University
Study ID
NCT06613633
Status
Completed

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • Third-generation TKI

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment, the characteristics of the distribution of lesions when the best response is achieved, the feasibility of SRT when the best response is achieved, and the phenotype of disease progression after EGFR-TKI resistance. In summary, this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI, which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC.

Key Dates

Start date
Sep 1, 2018
Status verified
Feb 2026
Primary completion
Aug 1, 2024
Completion
Feb 20, 2026

Study Design

Enrollment
4,000 participants (actual)

Arms

  • Arm: third-generation EGFR-TKI monotherapy

Primary Outcome Measure

Time to Best Response [ Time Frame: 5 years ]

Related Studies